← Back to Search

Diagnostic Test

MRI Scans for Prostate Cancer (PRIME Trial)

N/A
Recruiting
Led By Clare Allen, FRCR
Research Sponsored by University College, London
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men at least 18 years of age referred with clinical suspicion of prostate cancer
Fit to undergo all procedures listed in protocol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at an expected average of 30 days post-intervention
Awards & highlights

PRIME Trial Summary

This trial is comparing two types of MRI scans to see if one is better than the other at detecting prostate cancer.

Who is the study for?
This trial is for men over 18 suspected of having prostate cancer, with a PSA level ≤ 20ng/ml, and fit to undergo MRI scans and biopsies. It's not for those who've had previous prostate biopsies or MRIs, have contraindications to MRI or biopsy procedures, or have been treated for prostate cancer before.Check my eligibility
What is being tested?
The PRIME study is comparing two types of MRI scans in detecting significant prostate cancer: multiparametric (mpMRI) which uses IV contrast and biparametric (bpMRI) which does not. The goal is to see if bpMRI can match mpMRI's effectiveness without needing contrast.See study design
What are the potential side effects?
Potential side effects may include discomfort from the MRI procedure itself or reactions related to the use of IV contrast in mpMRI such as allergic reactions, nausea, headache, pain at injection site, or very rarely kidney problems.

PRIME Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man, 18 or older, suspected to have prostate cancer.
Select...
I am physically fit to undergo all required medical procedures.

PRIME Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at an expected average of 30 days post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and at an expected average of 30 days post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of men with clinically significant cancer
Secondary outcome measures
Agreement between bpMRI and mpMRI for radiological staging decision
Agreement between bpMRI and mpMRI for score of suspicion
Agreement between bpMRI and mpMRI for treatment eligibility
+4 more

PRIME Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: bpMRIExperimental Treatment1 Intervention
Biparametric MRI
Group II: mpMRIActive Control1 Intervention
Multiparametric MRI

Find a Location

Who is running the clinical trial?

University College, LondonLead Sponsor
831 Previous Clinical Trials
38,900,542 Total Patients Enrolled
23 Trials studying Prostate Cancer
26,598 Patients Enrolled for Prostate Cancer
Clare Allen, FRCRPrincipal InvestigatorUniversity College London Hospital
Shonit Punwani, PhD FRCRPrincipal InvestigatorUniversity College, London

Media Library

Biparametric MRI (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04571840 — N/A
Prostate Cancer Research Study Groups: mpMRI, bpMRI
Prostate Cancer Clinical Trial 2023: Biparametric MRI Highlights & Side Effects. Trial Name: NCT04571840 — N/A
Biparametric MRI (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04571840 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment cap of this clinical trial?

"To complete this study, 500 qualified participants must be enrolled. Potential enrollees can visit one of the many trial sites such as Jewish General Hospital in Montréal and University of Chicago located in Minnesota."

Answered by AI

Are there any Canadian facilities currently undertaking this research initiative?

"8 medical centres across North America are hosting this clinical trial. Participants will be able to find one close by, as the sites span Montréal, Chicago and New york along with 8 other cities. This should reduce travel needs for those who choose to join the study."

Answered by AI

Is enrollment for the clinical trial still available?

"Clinicaltrials.gov states that this research is still recruiting participants, with the initial posting occuring on April 5th 2022 and last update occurring on May 11th of the same year."

Answered by AI
~171 spots leftby Mar 2025